{"id":141677,"date":"2026-08-06T22:02:29","date_gmt":"2026-08-06T22:02:29","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/141677\/"},"modified":"2026-08-06T22:02:29","modified_gmt":"2026-08-06T22:02:29","slug":"novo-nordisk-cpsenovo-b-stock-still-looks-like-a-bargain-as-shares-fell-48","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/141677\/","title":{"rendered":"Novo Nordisk (CPSE:NOVO B) Stock Still Looks Like A Bargain As Shares Fell 48%"},"content":{"rendered":"\n

Get insights on thousands of stocks<\/a> from the global community of over 7 million individual investors at Simply Wall St. <\/p>\n

Novo Nordisk stock has given investors a mixed ride, with solid 1 year gains but a sharp decline over 3 years, even as the broader valuation checks still suggest the shares lean cheap compared with fundamentals. Recent news on blockbuster diabetes and obesity drugs on one side and a failed late stage cardiovascular trial on the other keeps the market focused on what price fairly reflects this balance. <\/p>\n

Over the past 3 years the share price is down 48.1%, which means long term holders are still sitting on a sizeable drawdown despite shorter term strength. <\/p>\n

Strong demand for Wegovy and Ozempic can support expectations for the core diabetes and obesity franchises, while the recent ziltivekimab trial failure highlights that pipeline setbacks may weigh on how much investors are willing to pay. <\/p>\n

Novo Nordisk scores highly on valuation checks, with 5 out of 6 metrics<\/a> pointing to the stock looking undervalued rather than expensive on the available measures. <\/p>\n

The issue now is whether the current price around US$307.60 already reflects these cross currents or still offers a margin of safety for investors who are comfortable with the risks around the pipeline and growth expectations. <\/p>\n

Novo Nordisk delivered 5.2% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.<\/a> <\/p>\n

Is Novo Nordisk a Bargain on Earnings? <\/p>\n

The P\/E ratio fits Novo Nordisk well because earnings are a key driver for how investors value large, established pharmaceutical companies. On this measure, Novo Nordisk trades on about 11.2x earnings, which is roughly half the pharmaceuticals industry average of 21.2x and also well below the peer group average of 23.7x. That is a sizeable gap for a business of this scale. <\/p>\n

The fair P\/E ratio that factors in Novo Nordisk’s margins, size and risk profile is 23.3x. Compared with the current 11.2x multiple, the stock trades at a wide discount to what this framework suggests investors might usually pay. Despite the recent attention around the failed ziltivekimab trial, the market multiple still prices Novo Nordisk below both peers and this tailored fair value marker. <\/p>\n

On the P\/E multiple, Novo Nordisk stock appears undervalued compared with both its industry and the fair ratio estimate. <\/p>\n

\"CPSE:NOVO<\/a> CPSE:NOVO B P\/E Ratio as at Aug 2026 <\/p>\n

See what the numbers say about this price \u2014 find out in our valuation breakdown.<\/a> <\/p>\n

The Novo Nordisk Narrative: What Would Justify Today’s Price? <\/p>\n

Simply Wall St Narratives pick up where the Novo Nordisk valuation puzzle leaves off by spelling out what assumptions about future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price. Each Narrative ties a specific fair value to a particular story about Novo Nordisk’s potential catalysts and risks, so you can track over time which version of events is actually unfolding on the Community page. <\/p>\n

The Simply Wall St community is split on Novo Nordisk, with some investors seeing a long runway around GLP 1 therapies, while others focus on capacity, access and competition risks. <\/p>\n

Bull case: roughly fairly valued <\/p>\n

“Despite current headwinds, penetration of GLP-1 therapies in both diabetes (only 7% of prescriptions) and obesity (less than 1% of those affected globally treated with branded medications) remains extremely low, suggesting a vast untapped patient pool that could drive significant long-term revenue growth as access and adoption increase\u2026” <\/p>\n

Read the full Bull Case<\/a> to see why Novo Nordisk could be undervalued<\/a> <\/p>\n

Bear case: 7% overvalued <\/p>\n

“Manufacturing capacity is constrained until roughly 2029, limiting volume growth regardless of demand\u2026” <\/p>\n

Read the full Bear Case<\/a> to see why Novo Nordisk could be overvalued<\/a> <\/p>\n

Do you think there’s more to the story for Novo Nordisk? Head over to our Community to see what others are saying!<\/a> <\/p>\n

The Bottom Line <\/p>\n

Novo Nordisk screens as undervalued on the market multiples used here, with the current P\/E well below both industry averages and the tailored fair ratio. That gap only closes if you assume the market is correctly pricing long term risks around the pipeline and execution on GLP 1 demand. The key question is whether that discount reflects a genuine margin of safety or a value trap if growth and access to obesity and diabetes treatments do not track the more optimistic expectations. For now, the crux of the bull versus bear debate is how much confidence you place in Novo Nordisk sustaining its core franchises while managing trial and capacity setbacks. <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n

Companies discussed in this article include NOVO-B.CO<\/a>. <\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply…\n","protected":false},"author":2,"featured_media":141678,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[1147,3754,272],"class_list":["post-141677","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-fair-value","tag-individual-investors","tag-novo-nordisk"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117050824857113947","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/141677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=141677"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/141677\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/141678"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=141677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=141677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=141677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}